• A
  • A
Font Size

Tips on your treatment with EYLEA

You'll want to do everything you can to get the most out of your treatment.

Eye appointment schedule
  • Stick to your scheduled appointments. If you must miss an appointment, reschedule it as soon as possible
Eye doctor
  • Follow all of your eye care team's instructions. Your doctor is your primary source for information and treatment recommendations
At home Amsler grid
  • Use the Amsler Grid at home to routinely check your vision at home.1 If you notice changes in your vision, call your doctor right away—don't wait for your next office visit1

Go beyond treatment

Managing your overall health is also important in caring for your vision.2,3

  • Control your weight, blood sugar, and blood pressure through diet and exercise2,3
  • Don’t smoke4
  • Join a support group in your area5
  • See a low vision specialist about lifestyle changes and vision aids6
  • Work with your eye care team to decide what lifestyle changes you can make so you can continue to do the things you enjoy.
  • Enroll in EYLEA4U®—If you need help with the cost of EYLEA, EYLEA4U patient support programs may be available to help you, if you are eligible.
Important Safety Information
  • EYLEA® (aflibercept) Injection is a prescription medication administered by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.
Top
Important Safety Information
  • EYLEA® (aflibercept) Injection is a prescription medication administered by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.
  • Injection into the eye with EYLEA can result in an infection in the eye and retinal detachment (separation of retina from back of the eye). Inflammation in the eye has been reported with the use of EYLEA.
  • In some patients, injections with EYLEA may cause a temporary increase in eye pressure within 1 hour of the injection. Sustained increases in eye pressure have been reported with repeated injections, and your doctor may monitor this after each injection.
  • There is a potential risk of serious and sometimes fatal side effects related to blood clots, leading to heart attack or stroke in patients receiving EYLEA.
  • Serious side effects related to the injection procedure with EYLEA are rare but can occur including infection inside the eye and retinal detachment.
  • The most common side effects reported in patients receiving EYLEA are increased redness in the eye, eye pain, cataract, moving spots in the field of vision, increased pressure in the eye, and vitreous (gel-like substance) detachment.
  • It is important that you contact your doctor right away if you think you might be experiencing any side effects, including eye pain or redness, light sensitivity, or blurring of vision, after an injection.
  • EYLEA is for prescription use only. For additional safety information, please talk to your doctor and see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Indications

EYLEA® (aflibercept) Injection is a prescription medicine approved for the treatment of patients with:

  • Wet Age-related Macular Degeneration (AMD): The recommended dose for EYLEA is 2 mg administered by injection in the eye every 2 months (8 weeks) following 3 initial monthly (every 4 weeks) injections. EYLEA may be dosed once per month, but in most patients, additional benefit was not seen with this dosing plan. Some patients may need monthly (every 4 weeks) dosing after the first 3 months (12 weeks).
  • Macular Edema following Retinal Vein Occlusion (RVO): The recommended dose for EYLEA is 2 mg administered by injection in the eye monthly (every 4 weeks).
  • Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR) in patients with DME: The recommended dose for EYLEA is 2 mg administered by injection in the eye every 2 months (8 weeks) following 5 initial monthly (every 4 weeks) injections. EYLEA may be dosed once per month, but in most patients, additional benefit was not seen with this dosing plan. Some patients may need monthly (every 4 weeks) dosing after the first 5 months (20 weeks).
Please see the full Prescribing Information for EYLEA.

The information contained herein is provided for general educational purposes. If you have any questions, talk to your doctor.

References:
  1. Facts about macular edema. National Institutes of Health, National Eye Institute Web site. https://nei.nih.gov/health/macular-edema/fact_sheet. Accessed October 5, 2016.
  2. Who is at risk for central retinal vein occlusion (CRVO)? American Academy of Ophthalmology (AAO EyeSmart) Web site. http://www.aao.org/eye-health/diseases/central-retinal-vein-occlusion-risk. Accessed October 5, 2016.
  3. Who is at risk for branch retinal vein occlusion (BRVO)? American Academy of Ophthalmology (AAO EyeSmart) Web site. http://www.aao.org/eye-health/diseases/branch-retinal-vein-occlusion-risk. Accessed October 5, 2016.
  4. Smoking and eye health. American Academy of Ophthalmology (AAO EyeSmart) Web site. http://www.aao.org/eye-health/tips-prevention/smokers. Accessed October 5, 2016.
  5. Support groups and other resources. American Foundation for the Blind Web site. http://www.afb.org/section.aspx?SectionID=64&DocumentID=3222. Accessed October 5, 2016.
  6. What is low vision? American Foundation for the Blind, VisionAware Web site. http://www.visionaware.org/info/your-eye-condition/eye-health/low-vision/123. Accessed October 5, 2016.